Sodium phenylbutyrate in Huntington's disease: A dose-finding study

Movement Disorders

Volumn 22, Issue 13, 2007, Pages 1962-1964

  Hogarth, Penelope ^a,b,d   Lovrecic, Luca ^c   Krainc, Dimitri ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Histone deacetylase inhibitor; Huntington's disease; Sodium phenylbutyrate

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; SODIUM PHENYLBUTYRATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY ODOR; CHOREA; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FEMALE; FLUSHING; GAIT DISORDER; GENE EXPRESSION; HEADACHE; HUMAN; HUNTINGTON CHOREA; HYPERGLYCEMIA; INSOMNIA; MALE; NAUSEA; PHENOTYPE; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SWEATING; SYNCOPE; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION; GENETIC MARKERS; HISTONE DEACETYLASES; HUMANS; HUNTINGTON DISEASE; LYMPHOCYTES; MALE; MIDDLE AGED; PHENYLBUTYRATES; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SODIUM;

EID: 36248970599     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21632     Document Type: Article

References (8)

1. Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001;413:739-743.
2. Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003;23:9418-9427.
3. Gardian G, Browne SE, Choi DK, et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 2005;280:556-563.
4. Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003;100:2041-2046.
5. Gilbert J, Baker SD, Bowling MK, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001;7:2292-2300.
6. Traynor BJ, Bruijn L, Conwit R, et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 2006;67:20-27.
7. Minamiyama M, Katsuno M, Adachi H, et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Human Mol Genet 2004;13:1183-1192.
8. Borovecki F, Lovrecic L, Zhou J, et al. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci USA 2005;102:11023-11028.